PDC*LINE PHARMA TO ATTEND UPCOMING SCIENTIFIC AND PARTNERING CONFERENCES THIS FALL
PDC*line Pharma, a biotech company developing a novel class of potent and off-the-shelf cancer immunotherapies to treat cancer patients, today announced that the Company will give presentations and attend to the following scientific and partnering conferences in Europe and US:
World Vaccine Congress Europe
Date: October 14-21, 2020
Presenter/attendance: Eric Halioua, CEO
Venue : Virtual event
Cell & Gene Strategy Meeting 2020
Date: October 22, 2020
Presenter/attendance: Eric Halioua, CEO
Venue: Virtual event
BIO-Europe
Date: October 26-20, 2020
Presenter/attendance: Eric Halioua, CEO and Laurent Levy, COO/CFO
Venue: Virtual event
World Immunotherapy Congress
Date: November 2-5, 2020
Presenter/attendance: Eric Halioua, CEO and Laurent Levy, COO/CFO
Venue: Virtual event
Neoantigen Based Therapies Summit 2020
Date: November 3-5, 2020
Presenter/attendance: Eric Halioua, CEO and Laurent Levy, COO/CFO
Venue: Virtual event
7th China Healthcare Summit
Date: November 9-13, 2020
Presenter/attendance: Eric Halioua, CEO and Laurent Levy, COO/CFO
Venue: Virtual event
PDC-LINE-PHARMA TO ATTEND UPCOMING SCIENTIFIC AND PARTNERING CONFERENCES THIS FALL.pdf
About PDC*line Pharma
Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of plasmacytoid dendritic cells (PDC*line). PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma focuses on the development of PDC*lung01, a candidate for non-small-cell lung cancer (NSCLC) currently in phase I/II trials, and PDC*neo with neoantigens in preclinical development. The company has a staff of 25, with an experienced management team. In March 2019, PDC*line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal is worth $123M, plus tiered royalties on net sales in Asia.
